[Cell cycle inhibitors in endocrine receptor positive breast cancer]. / Les inhibiteurs du cycle cellulaire et cancer du sein hormonodépendant.
Bull Cancer
; 104(2): 114-122, 2017 Feb.
Article
in Fr
| MEDLINE
| ID: mdl-28126188
ABSTRACT
Dysregulation of cellular cycle is a key component of carcinogenesis and its targeting represents an interesting approach. Recently, the development of selective inhibitors of the cycle targeting the cyclin-dependent kinases (CDK) 4 and 6 revived interest in this therapeutic class after the failure of pan-inhibitors. Palbociclib, ribociclib, and abemaciclib are the 3 drugs with the most advanced development. They demonstrated preclinical activity in luminal breast cancer models and are under clinical evaluation. The first available studies demonstrate the value of these compounds with an improved prognosis of metastatic patients in combination with endocrine therapy (palbociclib, ribociclib) or in monotherapy (abemaciclib). The results of ongoing studies will clarify the role of these agents in our new strategies and the individualisation of biomarkers will help to define patients who benefit most from this approach.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Protein Kinase Inhibitors
/
Cyclin-Dependent Kinase 4
/
Cyclin-Dependent Kinase 6
/
Neoplasms, Hormone-Dependent
/
Antineoplastic Agents
Limits:
Female
/
Humans
Language:
Fr
Journal:
Bull Cancer
Year:
2017
Document type:
Article